Effects of SKF525A, phenobarbital, fasting, and carnitine on the anticonvulsant activity and neurotoxicity of valproate in mice.
The anticonvulsant potency of valproate (VPA), as measured by the maximal electroshock seizure model in mice, was improved by pretreatment with the microsomal inhibitor SKF525A and by fasting, but was reduced by chronic phenobarbital pretreatment. Carnitine did not significantly alter the anticonvulsant properties of VPA. These findings suggest that the efficacy of VPA can be improved by factors that alter its metabolic pattern.
D000818:Animals; D002331:Carnitine / Q000627:therapeutic use; D005215:Fasting; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D009420:Nervous System / Q000187:drug effects; D010634:Phenobarbital / Q000494:pharmacology; D011335:Proadifen / Q000627:therapeutic use*; D012640:Seizures / Q000188:drug therapy*; D014635:Valproic Acid / Q000009:adverse effects / Q000627:therapeutic use*
D014635:Valproic Acid; D011335:Proadifen; D002331:Carnitine; D010634:Phenobarbital